CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Long-Term Clinical Outcomes With Sirolimus-Eluting Coronary StentsFive-Year Results of the RAVEL Trial
Marie-Claude Morice, MD, FACC, FESC*,*,
Patrick W. Serruys, MD, PhD, FACC ,
Paul Barragan, MD ,
Christoph Bode, MD ,
Gerrit-Anne Van Es, PhD||,
Hans-Peter Stoll, MD¶,
David Snead, PhD#,
Laura Mauri, MD, MSc, FACC**,
Donald E. Cutlip, MD, FACC** and
Eduardo Sousa, MD, PhD, FACC
* Institut Cardiovasculaire Paris Sud, Massy, France
Erasmus Medical Center, Rotterdam, the Netherlands
Clinique Beauregard, Marseille, France
Albert-Ludwigs-Universitätskliniken, Kardiologie, Freiburg, Germany
|| Cardialysis, Rotterdam, the Netherlands
¶ Cordis Clinical Research, Waterloo, Belgium
# Cordis Clinical Research, Warren, New Jersey
** Harvard Clinical Research Institute, Boston, Massachusetts
Instituto Dante Pazzanese, Sao Paulo, Brazil
Manuscript received April 5, 2007;
revised manuscript received June 11, 2007,
accepted June 18, 2007.
* Reprint requests and correspondence: Dr. Marie-Claude Morice, Institut Hospitalier Jacques Cartier, Avenue du Noyer Lambert, 91300 Massy, France. (Email: mc.morice{at}icps.com.fr).
Objectives: This study examined the clinical outcomes at 5 years in RAVEL (A Randomized Comparison of a Sirolimus-Eluting Stent With a Standard Stent for Coronary Revascularization), the first controlled trial of drug-eluting stents.
Background: The 6-month rate of angiographic coronary restenosis has been markedly lowered by sirolimus-eluting stents (SES). The long-term performance of drug-eluting stents, however, is under close scrutiny.
Methods: The trial included 238 patients (mean age 60.7 ± 10.4 years, 76% men) with a single, de novo native coronary artery lesion, randomly assigned to treatment with SES versus bare-metal stents (BMS). Rates of major adverse cardiac events (MACE), defined as all-cause mortality, myocardial infarction, and percutaneous or surgical revascularization up to 5 years of follow-up, and rates of stent thrombosis were compared between the 2 treatment groups.
Results: Complete datasets were available in 92.5% of patients treated with SES and 89.1% of patients assigned to BMS. The 1-, 3-, and 5-year rates of survival free from target lesion revascularization (TLR) were, respectively, 99.2%, 93.8%, and 89.7% in the SES group versus 75.9%, 75.0%, and 74.0% in the control group (p < 0.001; log-rank). Rates of all MACE at 5 years were 25.8% in patients treated with SES versus 35.2% in patients assigned to BMS (p = 0.03; log-rank). Rates of stent thrombosis, per protocol or by the Academic Research Consortium definitions, were similar in both groups.
Conclusions: The 5-year rate of TLR associated with SES was significantly lower than that with BMS. There was no apparent adverse effect associated with the use of SES, although the trial was not powered to examine uncommon complications.
|
Abbreviations and Acronyms
| | ARC = Academic Research Consortium | | BMS = bare-metal stent(s) | | MACE = major adverse cardiac events | | MI = myocardial infarction | | QCA = quantitative coronary angiography | | SES = sirolimus-eluting stent(s) | | TLR = target lesion revascularization | | TVR = target vessel revascularization |
|
Related Article
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2007 50: A31-A32.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
W. D. Paulson, N. Kipshidze, K. Kipiani, N. Beridze, M. V. DeVita, S. Shenoy, and S. S. Iyer
Safety and efficacy of local periadventitial delivery of sirolimus for improving hemodialysis graft patency: first human experience with a sirolimus-eluting collagen membrane (Coll-R)
Nephrol. Dial. Transplant.,
January 11, 2012;
(2012)
gfr667v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Sarno, B. Lagerqvist, O. Frobert, J. Nilsson, G. Olivecrona, E. Omerovic, N. Saleh, D. Venetzanos, and S. James
Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
Eur. Heart J.,
January 9, 2012;
(2012)
ehr479v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W. Park, I.-H. Chae, D.-S. Lim, K.-R. Han, H.-M. Yang, H.-Y. Lee, H.-J. Kang, B.-K. Koo, T. Ahn, J.-H. Yoon, et al.
Everolimus-Eluting Versus Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention The EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) Randomized Trial.
J. Am. Coll. Cardiol.,
October 25, 2011;
58(18):
1844 - 1854.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Raber, L. Wohlwend, M. Wigger, M. Togni, S. Wandel, P. Wenaweser, S. Cook, A. Moschovitis, R. Vogel, B. Kalesan, et al.
Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents: Results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE Trial
Circulation,
June 21, 2011;
123(24):
2819 - 2828.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Nakazawa, M. Nakano, F. Otsuka, J. N. Wilcox, R. Melder, S. Pruitt, F. D. Kolodgie, and R. Virmani
Evaluation of Polymer-Based Comparator Drug-Eluting Stents Using a Rabbit Model of Iliac Artery Atherosclerosis
Circ Cardiovasc Interv,
February 1, 2011;
4(1):
38 - 46.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Nakazawa, A. V. Finn, M. Vorpahl, E. R. Ladich, F. D. Kolodgie, and R. Virmani
Coronary Responses and Differential Mechanisms of Late Stent Thrombosis Attributed to First-Generation Sirolimus- and Paclitaxel-Eluting Stents
J. Am. Coll. Cardiol.,
January 25, 2011;
57(4):
390 - 398.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Simsek, M. Magro, E. Boersma, Y. Onuma, S. T. Nauta, M. P. Gaspersz, W. J. van der Giessen, R. T. van Domburg, P. W. Serruys, and on behalf of the Interventional Cardiologists of t
The Unrestricted Use of Sirolimus- and Paclitaxel-Eluting Stents Results in Better Clinical Outcomes During 6-Year Follow-Up Than Bare-Metal Stents: An Analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) Registries
J. Am. Coll. Cardiol. Intv.,
October 1, 2010;
3(10):
1051 - 1058.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Yamaji, T. Kimura, T. Morimoto, Y. Nakagawa, K. Inoue, Y. Soga, T. Arita, S. Shirai, K. Ando, K. Kondo, et al.
Very Long-Term (15 to 20 Years) Clinical and Angiographic Outcome After Coronary Bare Metal Stent Implantation
Circ Cardiovasc Interv,
October 1, 2010;
3(5):
468 - 475.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Garg and P. W. Serruys
Coronary Stents: Current Status
J. Am. Coll. Cardiol.,
August 31, 2010;
56(10_Suppl_S):
S1 - S42.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. W. Serruys, Y. Onuma, S. Garg, P. Vranckx, B. De Bruyne, M.-C. Morice, A. Colombo, C. Macaya, G. Richardt, J. Fajadet, et al.
5-Year Clinical Outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the Sirolimus-Eluting Stent in the Treatment of Patients With Multivessel De Novo Coronary Artery Lesions
J. Am. Coll. Cardiol.,
March 16, 2010;
55(11):
1093 - 1101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. De Felice, R. Fiorilli, A. Parma, M. Nazzaro, C. Musto, F. Sbraga, G. Caferri, and R. Violini
3-Year Clinical Outcome of Patients With Chronic Total Occlusion Treated With Drug-Eluting Stents
J. Am. Coll. Cardiol. Intv.,
December 1, 2009;
2(12):
1260 - 1265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Hoppmann, A. Erl, S. Turk, K. Tiroch, J. Mehilli, A. Schomig, A. Kastrati, and W. Koch
No Association of Chromosome 9p21.3 Variation With Clinical and Angiographic Outcomes After Placement of Drug-Eluting Stents
J. Am. Coll. Cardiol. Intv.,
November 1, 2009;
2(11):
1149 - 1155.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Herdeg, K. Gohring-Frischholz, K. K. Haase, T. Geisler, C. Zurn, U. Hartmann, J. Wohrle, T. Nusser, J. Dippon, A. E. May, et al.
Catheter-Based Delivery of Fluid Paclitaxel for Prevention of Restenosis in Native Coronary Artery Lesions After Stent Implantation
Circ Cardiovasc Interv,
August 1, 2009;
2(4):
294 - 301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Chacko, M. Mulhearn, V. Novack, L. Novack, L. Mauri, S. A. Cohen, J. Moses, M. B. Leon, and D. E. Cutlip
Impact of Target Lesion and Nontarget Lesion Cardiac Events on 5-Year Clinical Outcomes After Sirolimus-Eluting or Bare-Metal Stenting
J. Am. Coll. Cardiol. Intv.,
June 1, 2009;
2(6):
498 - 503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. C. H. Yu, T. W. H. Leung, J. S. Y. Lam, W. W. M. Lam, and L. K. S. Wong
Symptomatic Ostial Vertebral Artery Stenosis: Treatment with Drug-eluting Stents--Clinical and Angiographic Results at 1-year Follow-up1
Radiology,
April 1, 2009;
251(1):
224 - 232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/writing members:, J. Daemen, M. L. Simoons, W. Wijns, A. Bagust, G. Bos, J. M. Bowen, E. Braunwald, E. Camenzind, B. Chevalier, et al.
Meeting Report: ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007
Eur. Heart J.,
January 2, 2009;
30(2):
152 - 161.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Byrne, M. Leacche, D. E. Vaughan, and D. X. Zhao
Hybrid Cardiovascular Procedures
J. Am. Coll. Cardiol. Intv.,
October 1, 2008;
1(5):
459 - 468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Nishigaki, T. Yamazaki, A. Kitabatake, T. Yamaguchi, K. Kanmatsuse, I. Kodama, N. Takekoshi, H. Tomoike, M. Hori, M. Matsuzaki, et al.
Percutaneous Coronary Intervention Plus Medical Therapy Reduces the Incidence of Acute Coronary Syndrome More Effectively Than Initial Medical Therapy Only Among Patients With Low-Risk Coronary Artery Disease: A Randomized, Comparative, Multicenter Study
J. Am. Coll. Cardiol. Intv.,
October 1, 2008;
1(5):
469 - 479.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-J. Goy, U. Kaufmann, M. Hurni, S. Cook, F. Versaci, P. Ruchat, O. Bertel, M. Pieper, B. Meier, L. Chiarello, et al.
10-Year Follow-Up of a Prospective Randomized Trial Comparing Bare-Metal Stenting With Internal Mammary Artery Grafting for Proximal, Isolated De Novo Left Anterior Coronary Artery Stenosis: The SIMA (Stenting versus Internal Mammary Artery grafting) Trial
J. Am. Coll. Cardiol.,
September 2, 2008;
52(10):
815 - 817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hamdalla and D. J. Moliterno
Late drug-eluting stent thrombosis in unprotected left main coronary artery lesions--sometimes possible, but rarely definite or probable
Eur. Heart J.,
September 1, 2008;
29(17):
2064 - 2066.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. V. Anderson
Drug-Eluting Stents: Life Insurance With a Better Death Benefit
J. Am. Coll. Cardiol.,
May 27, 2008;
51(21):
2025 - 2027.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the Year in JACC 2007
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
|
|
|
